Acting Chief Medical Officer
Christine Haller, MD received a B.S. in Chemical Engineering at the University of Utah, and an MS/MD from the UC Berkeley/UC San Francisco Joint Medical program. She did a residency in Clinical Pathology and completed a fellowship in Medical Toxicology and Clinical Pharmacology at UC San Francisco. After 7 years as an NIH-funded Principal Investigator in clinical research and Assistant Professor of Medicine at UCSF, she left academics to join the early development drug safety group at Amgen, and ultimately became the head of the Bone Therapeutic Area safety group. After 6 years at Amgen, she took a position in clinical development at BioMarin where she led a clinical group involved in development of new therapies for rare genetic diseases including the mucopolysaccharidoses, achondroplasia and Pompe disease. She led the program working on the global approval of Vimizim for Morquio A syndrome. Subsequently she took a position as the head of Drug Safety and Pharmacovigilance at Ultragenyx and then was promoted to Senior Vice President of Clinical Development where she led the vestronindase alpha development program through regulatory approval for the treatment of MPS VII, and supervised development efforts for other rare metabolic genetic disorders.
Since 2018, Dr Haller has been an independent clinical consultant for established pharmaceutical companies, smaller biotechs and venture start-ups to support development of new therapeutics for rare diseases including small molecules, biologics and gene therapies.